Paul James Hoover, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lupus Nephritis | 3 | 2020 | 320 | 1.060 |
Why?
|
Public-Private Sector Partnerships | 1 | 2020 | 123 | 0.630 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2020 | 330 | 0.600 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2020 | 794 | 0.520 |
Why?
|
Drug Industry | 1 | 2020 | 793 | 0.430 |
Why?
|
Glucocorticoids | 2 | 2017 | 2170 | 0.340 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2785 | 0.320 |
Why?
|
Ion Channel Gating | 1 | 2011 | 429 | 0.320 |
Why?
|
Calcium Channels | 1 | 2011 | 624 | 0.290 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4213 | 0.210 |
Why?
|
Kidney | 3 | 2023 | 7064 | 0.190 |
Why?
|
Single-Cell Analysis | 2 | 2023 | 2531 | 0.170 |
Why?
|
Health Services Accessibility | 1 | 2016 | 5510 | 0.150 |
Why?
|
Calcium | 1 | 2011 | 5793 | 0.150 |
Why?
|
Renal Artery | 1 | 2019 | 353 | 0.140 |
Why?
|
Kidney Tubules | 1 | 2019 | 448 | 0.140 |
Why?
|
Gene Expression Profiling | 3 | 2023 | 9507 | 0.140 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2020 | 336 | 0.140 |
Why?
|
Influenza A virus | 1 | 2020 | 460 | 0.130 |
Why?
|
Membrane Proteins | 2 | 2020 | 7895 | 0.130 |
Why?
|
Exercise Tolerance | 1 | 2020 | 849 | 0.120 |
Why?
|
Nephrotic Syndrome | 1 | 2018 | 382 | 0.120 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2020 | 645 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1395 | 0.110 |
Why?
|
Microfluidics | 1 | 2019 | 675 | 0.110 |
Why?
|
Scleroderma, Localized | 1 | 2014 | 87 | 0.110 |
Why?
|
Biopsy | 3 | 2020 | 6816 | 0.100 |
Why?
|
Keratinocytes | 1 | 2017 | 879 | 0.100 |
Why?
|
Kidney Diseases | 1 | 2023 | 2102 | 0.100 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2039 | 0.100 |
Why?
|
Cryptosporidium parvum | 2 | 2002 | 35 | 0.100 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1465 | 0.090 |
Why?
|
Lung Diseases, Interstitial | 1 | 2020 | 935 | 0.090 |
Why?
|
Lymphocytes | 1 | 2019 | 2611 | 0.090 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 2002 | 767 | 0.090 |
Why?
|
Toll-Like Receptor 4 | 1 | 2014 | 586 | 0.090 |
Why?
|
Fibronectins | 1 | 2014 | 725 | 0.090 |
Why?
|
Quantitative Trait Loci | 1 | 2018 | 2127 | 0.090 |
Why?
|
Monocytes | 1 | 2019 | 2591 | 0.080 |
Why?
|
Hypertension, Pulmonary | 1 | 2020 | 1605 | 0.080 |
Why?
|
Nonlinear Dynamics | 1 | 2011 | 496 | 0.080 |
Why?
|
Psoriasis | 1 | 2017 | 947 | 0.080 |
Why?
|
Influenza, Human | 1 | 2020 | 1540 | 0.080 |
Why?
|
Flow Cytometry | 1 | 2019 | 5904 | 0.080 |
Why?
|
Administration, Oral | 1 | 2016 | 4041 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2016 | 3550 | 0.070 |
Why?
|
Endothelial Cells | 1 | 2020 | 3586 | 0.070 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2019 | 2173 | 0.070 |
Why?
|
Endoplasmic Reticulum | 1 | 2011 | 1129 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4642 | 0.060 |
Why?
|
Medication Adherence | 1 | 2016 | 2190 | 0.060 |
Why?
|
Medicaid | 1 | 2016 | 2843 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4728 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7863 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2002 | 6091 | 0.050 |
Why?
|
HEK293 Cells | 1 | 2011 | 4294 | 0.050 |
Why?
|
Cell Membrane | 1 | 2011 | 3664 | 0.050 |
Why?
|
Dibenzothiepins | 1 | 2020 | 8 | 0.040 |
Why?
|
Thiepins | 1 | 2020 | 5 | 0.040 |
Why?
|
United States | 2 | 2020 | 73121 | 0.040 |
Why?
|
Melanoma | 1 | 2018 | 5740 | 0.040 |
Why?
|
Fibrosis | 2 | 2019 | 2076 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15880 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7451 | 0.040 |
Why?
|
Humans | 14 | 2023 | 768451 | 0.040 |
Why?
|
T Cell Transcription Factor 1 | 1 | 2018 | 72 | 0.040 |
Why?
|
Vacuolar Proton-Translocating ATPases | 1 | 2020 | 195 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18048 | 0.040 |
Why?
|
Triazines | 1 | 2020 | 312 | 0.040 |
Why?
|
Incidence | 1 | 2016 | 21552 | 0.040 |
Why?
|
Oxazines | 1 | 2020 | 357 | 0.040 |
Why?
|
Methyltransferases | 1 | 2020 | 375 | 0.030 |
Why?
|
Vascular Resistance | 1 | 2020 | 941 | 0.030 |
Why?
|
Morpholines | 1 | 2020 | 583 | 0.030 |
Why?
|
Apyrase | 1 | 2018 | 374 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 501 | 0.030 |
Why?
|
Respiratory Mechanics | 1 | 2020 | 722 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9505 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2023 | 2889 | 0.030 |
Why?
|
Pyridones | 1 | 2020 | 819 | 0.030 |
Why?
|
Epidermis | 1 | 2017 | 539 | 0.030 |
Why?
|
Atrophy | 1 | 2019 | 1648 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2023 | 22293 | 0.030 |
Why?
|
Oxygen Consumption | 1 | 2020 | 1882 | 0.030 |
Why?
|
Bleomycin | 1 | 2014 | 495 | 0.030 |
Why?
|
Risk Factors | 2 | 2019 | 74915 | 0.030 |
Why?
|
Myofibroblasts | 1 | 2014 | 232 | 0.030 |
Why?
|
Exercise Test | 1 | 2020 | 2186 | 0.020 |
Why?
|
RNA, Ribosomal, 18S | 2 | 2002 | 56 | 0.020 |
Why?
|
Signal Transduction | 1 | 2014 | 23638 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2018 | 2358 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4077 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 3816 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2014 | 2477 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2204 | 0.020 |
Why?
|
Genome-Wide Association Study | 2 | 2020 | 12774 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2018 | 6241 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2016 | 65409 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2910 | 0.020 |
Why?
|
Antigens, CD | 1 | 2018 | 4029 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 22365 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2017 | 11674 | 0.020 |
Why?
|
Pyridines | 1 | 2020 | 2888 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3063 | 0.020 |
Why?
|
Alleles | 1 | 2018 | 6890 | 0.020 |
Why?
|
Ligands | 1 | 2014 | 3281 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2020 | 4417 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2014 | 2003 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15609 | 0.020 |
Why?
|
Collagen | 1 | 2014 | 2646 | 0.020 |
Why?
|
Adult | 4 | 2020 | 223542 | 0.010 |
Why?
|
Exercise | 1 | 2020 | 5940 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20231 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13655 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 17149 | 0.010 |
Why?
|
RNA, Protozoan | 1 | 2001 | 46 | 0.010 |
Why?
|
Micromanipulation | 1 | 2001 | 53 | 0.010 |
Why?
|
DNA, Ribosomal | 1 | 2002 | 301 | 0.010 |
Why?
|
Skin | 1 | 2014 | 4520 | 0.010 |
Why?
|
Male | 4 | 2020 | 364781 | 0.010 |
Why?
|
Chronic Disease | 1 | 2014 | 9382 | 0.010 |
Why?
|
Middle Aged | 3 | 2020 | 223418 | 0.010 |
Why?
|
Female | 4 | 2020 | 396943 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 16029 | 0.010 |
Why?
|
Animals | 4 | 2018 | 169418 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 2002 | 14728 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 60045 | 0.010 |
Why?
|
Mice | 1 | 2018 | 82045 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2019 | 81834 | 0.010 |
Why?
|
Adolescent | 1 | 2018 | 89168 | 0.010 |
Why?
|
Genotype | 1 | 2002 | 13047 | 0.000 |
Why?
|
Aged | 1 | 2020 | 171520 | 0.000 |
Why?
|